Literature DB >> 22550960

Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation.

Speranta Iacob1, Vito R Cicinnati, Alexander Dechêne, Monika Lindemann, Falko M Heinemann, Vera Rebmann, Stanislav Ferencik, Georgios C Sotiropoulos, Irinel Popescu, Peter A Horn, Guido Gerken, Andreas Paul, Susanne Beckebaum.   

Abstract

BACKGROUND: Biliary strictures after liver transplantation (LT) are a major cause of morbidity and reduced graft survival. AIMS: The purpose of this study was to investigate genetic, immunological and clinical risk factors for the occurrence of post-LT ischaemic type biliary lesions (ITBLs) and biliary anastomotic strictures (AS).
METHODS: Clinical and laboratory data, chemokine receptor (CCR) genotypes, chemotactic cytokines and anti-major-histocompatibility complex antibodies in serum were investigated in 162 LT patients.
RESULTS: In the univariate analysis, older donor and recipient age, partial LT, high peak aspartate aminotransaminase (AST) levels and CC chemokine receptor 5 delta32 loss-of-function mutation (CCR5Δ32) were associated with ITBL, whereas LT for acute liver failure (ALF), ABO-compatible non-identical LT, presence of donor-specific anti-human leucocyte antigen (HLA) class II antibodies and fractalkine receptor (CX3CR1)-249II allele were associated with AS. In the multivariate analysis, CCR5Δ32 was an independent risk factor for ITBL, whereas LT for ALF, ABO-compatible non-identical LT, and CX3CR1-249II allele remained predictive for AS. Serum levels of interferon-gamma and interleukin (IL)-6 as well as IL-10 were significantly increased in patients with biliary strictures.
CONCLUSION: Specific chemokine receptor polymorphisms of the recipient are associated with development of post-LT biliary strictures. Altered cytokine profile may contribute to enhanced fibrotic tissue remodelling and biliary stricture formation. Screening of anti-HLA antibodies might be useful for early identification of at-risk patients who could benefit from closer surveillance and tailored immunosuppressive regimen. Our findings may have relevance for prediction and management of post-LT biliary strictures.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22550960     DOI: 10.1111/j.1478-3231.2012.02810.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  11 in total

1.  The role of donor-specific HLA alloantibodies in liver transplantation.

Authors:  J G O'Leary; A J Demetris; L S Friedman; H M Gebel; P F Halloran; A D Kirk; S J Knechtle; S V McDiarmid; A Shaked; P I Terasaki; K J Tinckam; S J Tomlanovich; K J Wood; E S Woodle; A A Zachary; G B Klintmalm
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

Review 2.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

3.  Technique of subnormothermic ex vivo liver perfusion for the storage, assessment, and repair of marginal liver grafts.

Authors:  Jan M Knaak; Vinzent N Spetzler; Nicolas Goldaracena; Kristine S Louis; Nazia Selzner; Markus Selzner
Journal:  J Vis Exp       Date:  2014-08-13       Impact factor: 1.355

4.  Liver Preservation by Aortic Perfusion Alone Compared With Preservation by Aortic Perfusion and Additional Arterial Ex Situ Back-Table Perfusion With Histidine-Tryptophan-Ketoglutarate Solution: A Prospective, Randomized, Controlled, Multicenter Study.

Authors:  Gerd Otto; Michael Heise; Jochen Thies; Michael Pitton; Jens Schneider; Gernot Kaiser; Peter Neuhaus; Otto Kollmar; Michael Barthels; Josef Geks; Wolf Otto Bechstein; Achim Hellinger; Jürgen Klempnauer; Winfried Padberg; Nils Frühauf; Andre Ebbing; Dietmar Mauer; Astrid Schneider; Robert Kwiecien; Kai Kronfeld
Journal:  Transplant Direct       Date:  2017-06-26

5.  Influence of Type 2 Diabetes Mellitus and Preoperative Hemoglobin A1c Levels on Outcomes of Liver Transplantation.

Authors:  Meagan Gray; Sanjeev Singh; Stephen D Zucker
Journal:  Hepatol Commun       Date:  2019-02-20

6.  Intensified Endoscopic Evaluation for Biliary Complications After Orthotopic Liver Transplantation.

Authors:  Tim R Glowka; Caroline Karlstetter; Tobias J Weismüller; Tim O Vilz; Christian P Strassburg; Jörg C Kalff; Steffen Manekeller
Journal:  Ann Transplant       Date:  2021-04-06       Impact factor: 1.530

7.  A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial.

Authors:  Yingcai Zhang; Jiebin Zhang; Huimin Yi; Jun Zheng; Jianye Cai; Wenjie Chen; Tongyu Lu; Liang Chen; Cong Du; Jianrong Liu; Jia Yao; Hui Zhao; Guoying Wang; Binsheng Fu; Tong Zhang; Jian Zhang; Genshu Wang; Hua Li; Andy Peng Xiang; Guihua Chen; Shuhong Yi; Qi Zhang; Yang Yang
Journal:  Stem Cell Res Ther       Date:  2021-04-16       Impact factor: 6.832

Review 8.  The Human Immune Response to Cadaveric and Living Donor Liver Allografts.

Authors:  Angus Hann; Daniel-Clement Osei-Bordom; Desley A H Neil; Vincenzo Ronca; Suz Warner; M Thamara P R Perera
Journal:  Front Immunol       Date:  2020-06-22       Impact factor: 7.561

9.  HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level.

Authors:  Katharina Willuweit; Alexandra Frey; Lisa Bieniek; Andreas Heinold; Matthias Büchter; Peter A Horn; Heiner Wedemeyer; Kerstin Herzer
Journal:  BMC Gastroenterol       Date:  2020-08-27       Impact factor: 3.067

10.  Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies.

Authors:  Safak Gül-Klein; Henriette Hegermann; Robert Röhle; Moritz Schmelzle; Frank Tacke; Wenzel Schöning; Robert Öllinger; Tomasz Dziodzio; Patrick Maier; Julius M Plewe; David Horst; Igor Maximilian Sauer; Johann Pratschke; Nils Lachmann; Dennis Eurich
Journal:  J Inflamm Res       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.